K. Strimbu and J. A. , What are Biomarkers?, Curr. Opin. HIV AIDS, vol.5, issue.6, pp.463-466, 2010.

R. S. Vasan, Biomarkers of Cardiovascular Disease, Circulation, vol.113, issue.19, pp.2335-2362, 2006.

, World Intellectual Property Indicators, 2016.

J. F. Paone, T. P. Waalkes, R. R. Baker, and J. H. Shaper, Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma, J. Surg. Oncol, vol.15, issue.1, pp.59-66, 1980.

W. D. Bostick, M. S. Denton, and S. R. Dinsmore, Bioluminescence methods for enzymatic determinations, US4357420 A, 1982.

, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Biomarkers Definitions Working Group, vol.69, issue.3, pp.89-95, 2001.

, NCI Dictionary of Cancer Terms, p.5, 2017.

R. Frank and R. Hargreaves, Clinical biomarkers in drug discovery and development, Nat. Rev. Drug Discov, vol.2, issue.7, pp.566-580, 2003.

J. Romanetto, Intérêt des marqueurs biologiques dans les essais cliniques, 2011.

G. Novelli, C. Ciccacci, P. Borgiani, M. P. Amati, and E. Abadie, Genetic tests and genomic biomarkers: regulation, qualification and validation, Clin. Cases Miner. Bone Metab, vol.5, issue.2, pp.149-154, 2008.

E. Phizicky, P. I. Bastiaens, H. Zhu, M. Snyder, and S. Fields, Protein analysis on a proteomic scale, Nature, vol.422, issue.6928, pp.208-215, 2003.

N. L. Henry and D. F. Hayes, Cancer biomarkers, Mol. Oncol, vol.6, issue.2, pp.140-146, 2012.

R. Mayeux, Biomarkers: Potential Uses and Limitations, NeuroRx, vol.1, issue.2, pp.182-188, 2004.

, Réflexion prospective autour des biomarqueurs (Études du Pipame)-DGCIS : Prospective, études économiques et évaluation

, Biomarqueurs-Utilisation au cours du développement et pour l'enregistrement des médicaments-TR4G16-00.pdf

, HAS-Test compagnon associé à une thérapie ciblée : définitions et méthode d'évaluation

J. K. Aronson, Research priorities in biomarkers and surrogate end-points, Br. J. Clin. Pharmacol, vol.73, issue.6, pp.900-907, 2012.

J. K. Aronson, Biomarkers and surrogate endpoints, Br. J. Clin. Pharmacol, vol.59, issue.5, pp.491-494, 2005.

W. S. Richter, Imaging biomarkers as surrogate endpoints for drug development, Eur. J. Nucl. Med. Mol. Imaging, vol.33, pp.6-10, 2006.

C. Zhang, H. Hong, D. L. Mendrick, Y. Tang, and F. Cheng, Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science, Biomark. Med, vol.9, issue.11, pp.1241-1252, 2015.

L. Becquemont, Biomarqueurs dans le développement des médicaments

M. M. Bertagnolli, A. G. Zauber, and S. Solomon, Prostaglandin Inhibition and Cardiovascular Risk: Maybe Timing Really Is Everything, Cancer Prev. Res. (Phila. Pa.), vol.2, issue.3, pp.195-196, 2009.

P. Sahu, N. Pinkalwar, R. Dahr-dubey, S. Paroha, S. Chatterjee et al., Biomarkers: An Emerging Tool for Diagnosis of a Disease and Drug Development, Cancer Biomarker Discovery, vol.I, issue.1, pp.9-16, 2011.

A. Huriez, Biomarqueurs, pp.139-140, 2010.

S. I. Sherwani, H. A. Khan, A. Ekhzaimy, A. Masood, and M. K. Sakharkar, Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients, Biomark. Insights, vol.11, pp.95-104, 2016.

B. Leem-comité-biotech and . Partner, Le biomarqueur comme outil de diagnostic compagnon de produits thérapeutiques, p.16, 2010.

, Les biomarqueurs, les produits de santé et l'AFSSAPS," Cahier d'acteur

, Les progrès de la génétique, vers une médecine de précision ? Les enjeux scientifiques, technologiques, sociaux et éthiques de la médecine personnalisée

J. Mestre-ferrandiz, J. Sussex, and A. Towse, United Kingdom: Office of Health Economics, 2012.

, The Pharmaceutical Industry in Figures, p.12, 2014.

, Les enjeux de la qualité dans l'efficacité transversale d'un projet de recherche médicale

, Statistique-Vocabulaire et symboles-Partie 1: Termes statistiques généraux et termes utilisés en calcul des probabilités, vol.28, pp.3534-3535, 2006.

J. Daigle, L'utilisation des courbes ROC dans l'évaluation des tests diagnostiques de laboratoire clinique : Application à l'étude de la pneumonite d'hypersensibilité. Essai présenté à la Faculté des étues supérieures de l'Université Laval pour l'obtention du grade de maître ès sciences

T. G. Angelini and C. Emanueli, MicroRNAs as clinical biomarkers?, Front. Genet, vol.6, issue.240, 2015.

, Ablation des ovaires d'Angelina Jolie: peut-on anticiper le cancer grâce à la génétique?, p.22, 2016.

, Prédispositions génétiques-Facteurs de risque | Institut National Du Cancer, p.22, 2016.

J. D. Lewis, The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease, Gastroenterology, vol.140, issue.6, pp.1817-1826, 2011.

G. Lech, R. S?otwi?ski, M. S?odkowski, and I. W. Krasnod?bski, Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances, World J. Gastroenterol, vol.22, issue.5, p.1745, 2016.
DOI : 10.3748/wjg.v22.i5.1745

URL : https://doi.org/10.3748/wjg.v22.i5.1745

K. Lin, J. M. Croswell, H. Koenig, C. Lam, and A. Maltz, Prostate-Specific AntigenBased Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality (US), 2011.

M. Nowak, ?. Janas, G. Stachowiak, T. Stetkiewicz, and J. R. Wilczy?ski, Current clinical application of serum biomarkers to detect ovarian cancer, Przegla? d Menopauzalny Menopause Rev, vol.14, issue.4, pp.254-259, 2015.

W. J. Geldenhuys, S. M. Abdelmagid, P. J. Gallegos, and F. F. Safadi, Parkinson's disease biomarker: a patent evaluation of WO2013153386, Expert Opin. Ther. Pat, vol.24, issue.8, pp.947-951, 2014.

A. J. Noyce, A. J. Lees, and A. Schrag, The prediagnostic phase of Parkinson's disease, J Neurol Neurosurg Psychiatry, pp.2015-311890, 2016.

A. Kazlauskaite, Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65, Biochem. J, vol.460, issue.1, pp.127-139, 2014.

A. Kazlauskaite, Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity, Open Biol, vol.4, issue.3, p.130213, 2014.

D. Narendra, J. E. Walker, and R. Youle, Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism, Cold Spring Harb. Perspect. Biol, vol.4, issue.11, 2012.

D. Alessi and M. Muqit, Parkinson's disease biomarker, 2013.

C. Chenevier-gobeaux, Nouveaux biomarqueurs de la pathologie cardiovasculaire et infectieuse en médecine d'urgence, Réanimation, vol.19, issue.7, pp.648-654, 2010.
DOI : 10.1016/j.reaurg.2010.10.004

T. Omland, A sensitive cardiac troponin T assay in stable coronary artery disease, N. Engl. J. Med, vol.361, issue.26, pp.2538-2547, 2009.

Q. Guo, Identification of novel genetic markers of breast cancer survival, J. Natl. Cancer Inst, vol.107, issue.5, 2015.

H. Ueno, H. Mochizuki, K. Hatsuse, K. Hase, and T. Yamamoto, Indicators for Treatment Strategies of Colorectal Liver Metastases, Ann. Surg, vol.231, issue.1, p.59, 2000.

T. Mala, G. Bøhler, Ø. Mathisen, A. Bergan, and O. Søreide, Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome?, World J. Surg, vol.26, issue.11, pp.1348-1353, 2002.
DOI : 10.1007/s00268-002-6231-x

C. Giessen, Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer, Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med, vol.35, issue.10, pp.10237-10248, 2014.

W. H. Robinson, T. M. Lindstrom, R. K. Cheung, and J. Sokolove, Mechanistic biomarkers for clinical decision making in rheumatic diseases, Nat. Rev. Rheumatol, vol.9, issue.5, pp.267-276, 2013.

J. Zou, Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes, PLoS ONE, vol.10, issue.8, 2015.

A. Palaniappan, K. Ramar, and S. Ramalingam, Computational Identification of Novel Stage-Specific Biomarkers in Colorectal Cancer Progression, PLOS ONE, vol.11, issue.5, p.156665, 2016.
DOI : 10.1371/journal.pone.0156665

URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0156665&type=printable

J. Lu, High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer, Oncotarget, vol.7, issue.27, pp.41758-41766, 2016.
DOI : 10.18632/oncotarget.9676

URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=9676&path%5B%5D=30304

L. Zhao, Identification of key metabolic changes in renal interstitial fibrosis rats using metabonomics and pharmacology, Sci. Rep, vol.6, p.27194, 2016.

S. , HLA-B*5701 screening for hypersensitivity to abacavir, N. Engl. J. Med, vol.358, issue.6, pp.568-579, 2008.

, DVS Biomarqueurs et Tests Compagnons / aviesan, p.29, 2016.

S. , Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet Lond. Engl, vol.359, issue.9308, pp.727-732, 2002.

S. Hetherington, Genetic variations in HLA-B region and hypersensitivity reactions to abacavir, Lancet Lond. Engl, vol.359, issue.9312, pp.1121-1122, 2002.

A. Kubo, H. Hashimoto, N. Takahashi, and Y. Yamada, Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer, World J. Gastroenterol, vol.22, issue.2, pp.887-894, 2016.

T. Klag, G. Cantara, U. Sechtem, and A. Athanasiadis, Interleukin-6 Kinetics can be Useful for Early Treatment Monitoring of Severe Bacterial Sepsis and Septic Shock, Infect. Dis. Rep, vol.8, issue.1, 2016.

, Qu'est-ce que la Propriété Intellectuelle ?

, Institut national de la propriété Industrielle : les droits de la propriété intellectuelle et industrielle au service de la démarche d'innovation, p.25, 2016.

C. May, Venise : aux origines de la propriété intellectuelle, Économie Polit, vol.14, issue.2, pp.6-21, 2002.

S. Lapointe, L'Histoire des Brevets, p.18, 2017.

E. P. Office, États membres de l'Organisation européenne des brevets

E. P. Office, Fondements juridiques

, Aperçu du cadre juridique et réglementaire de la propriété intellectuelle aux États Unis d'Amérique, p.5, 2017.

. Yumpu and . Brevets-inpi, Chiffres clés, p.25, 2004.

V. Lambillotte, An Overview of Patentable Subject Matter and the Effect of Mayo Collaborative Services v, Case West. Reserve Law Rev, vol.63, issue.2, pp.635-651, 2012.

, A propos de la brevetabilité de traitements thérapeutiques individualisés à travers une comparaison des législations européennes et américaines par Kian TAWADJOH | Les blogs pédagogiques de l'Université Paris Ouest, 2016.

, REVISITING THE COMPROMISE OF 35 USC § 287(C)-v16p299.pdf

F. Faivre-petit, Le système des brevets américains exige (toujours) plus que la nature

, Rapport de la Commission au Parlement européen et au Conseil-Évolution et implications du droit des brevets dans le domaine de la biotechnologie et du génie génétique, p.1, 2016.

E. P. Office, Directives relatives à l'examen pratiqué, p.1, 2016.

J. Pierre, La brevetabilité du médicament en France : René Lemay, Santé publique et brevetabilité du médicament, Rev. Hist. Pharm, vol.57, issue.203, pp.517-518, 1969.

, Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions, 2016.

L. Marino, Propriété Industrielle, LexisNexis, vol.3, pp.24-30, 2014.

G. M. Gradi, Patenting biotechnologies: the European Union Directive 98/44/EC of the European parliament and of the council of 6th July 1998 on the legal protection of biotechnological inventions, Forum Genoa Italy, vol.9, issue.3, pp.25-36, 1999.

E. P. Office, Chambres de recours, p.4, 2017.

A. Casalonga, Conditions de brevetabilité, 2013.

, T 385/86 "Détermination non invasive de valeurs" / BRUKER-JO OEB 8, 1988.

, T 655/92-NYCOMED AS / Advanced Magnetics Inc-JO OEB, 1998.

B. Knüttel, Procédé pour la détermination non-invasive des valeurs de mesure à l'intérieur d'un corps vivant, EP0095124 A1, 1983.

U. Schröder and L. G. Salford, Agent de contraste et de diagnostic, EP0166755, vol.1, 1988.

, T 964/99, vol.29, 2001.

J. Tamada, Device for sampling of substances using alternating polarity, EP0766577 B1, vol.10, 2003.

J. O. Oeb, G 1/04 "Diagnostic methods, 2004.

, T 19/86 "Porcs II"-JO OEB 1-2, 1987.

, Adrenaline/MEDCO RESEARCH (unpublished), T 233/96, p.5, 2000.

J. Albrecht, Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection, vol.0956861, 1999.

, Combination therapy HCV/SCHERING (unpublished), 2006.

, Fulvestrant for treating resistant breast cancer/ASTRA ZENECA AB (unpublished), 2013.

, du 17 décembre 2010-Guillaume Bensussan | Les blogs pédagogiques de l'Université, p.2, 1403.

, Justia Law, p.18, 1980.

A. M. Chakrabarty and S. T. Kellogg, Bacteria capable of dissimilation of environmentally persistent chemical compounds, US4535061 A, vol.13, 1985.

A. M. Chakrabarty, Bioengineered bugs, drugs and contentious issues in patenting, Bioeng. Bugs, vol.1, issue.1, pp.2-8, 2010.

N. Seckel and P. Signore, Cours de droit américain des brevets, pp.2014-2013

E. R. Gold and J. Carbone, Myriad Genetics: In the eye of the policy storm, Genet. Med. Off. J. Am. Coll. Med. Genet, vol.12, issue.4, pp.39-70, 2010.

A. M. Fialho and A. M. Chakrabarty, Patent controversies and court cases, Cancer Biol. Ther, vol.13, issue.13, pp.1229-1234, 2012.

E. Seidman and Y. Theoret, Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage, vol.6355623, 2002.

E. Seidman and Y. Théorêt, Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders, vol.6680302, 2004.

A. S. Kesselheim, J. Karlawish, ;. Mayo, C. Services, D. Mayo-medical et al., Biomarkers unbound-the Supreme Court's ruling on diagnostic-test patents, N. Engl. J. Med, vol.366, issue.25, pp.2338-2340, 2012.

B. R. Dorn, Mayo v. Prometheus: A Year Later, ACS Med. Chem. Lett, vol.4, issue.7, pp.572-573, 2013.

J. F. Aceto, Patent Portfolios After Myriad, How to Fit in Those New Genes?, ACS Med. Chem. Lett, vol.4, issue.8, pp.681-683, 2013.

F. Tetaz, Mayo v. Prometheus," avril-2012, p.2, 2015.

A. S. Kesselheim, R. M. Cook-deegan, D. E. Winickoff, and M. M. Mello, Gene Patenting-The Supreme Court Finally Speaks, N. Engl. J. Med, vol.369, issue.9, pp.869-875, 2013.

, Association for Molecular Pathology v. Myriad Genetics, Inc. (06/13/2013), p.29, 2016.

, MYRIAD La Cour Suprême des Etats-Unis revient sur plus de 30 ans de pratique : l'ADN isolé n'est à présent plus brevetable ! Mauvaise passe pour les inventions en biotechnologies (plus) protégées sur le territoire américain.-2013 06 Article Myriad_FFP.pdf

J. M. Conley, R. Cook-deegan, and G. Lázaro-muñoz, MYRIAD AFTER MYRIAD: THE PROPRIETARY DATA DILEMMA, N. C. J. Law Technol, vol.15, issue.4, pp.597-637, 2014.

, Lois de la nature et idées abstraites : nouvelle tentative de clarification par l, Office Américain des Brevets

, Interim Guidance on Subject Matter Eligibility | USPTO, issue.16, 2014.

, Subject Matter Eligibility Examples: Life Sciences, p.6, 2016.

M. H. Skolnick, Sondes d'acide nucléique comprenant un fragment gène de susceptibilité du cancer du sein et des ovaires associé à 17Q, EP0705902, vol.2, p.6, 2008.

N. Momeni and B. L. Persson, Nouveau biomarqueur et ses utilisations dans le diagnostic, le traitement de l'autisme, WO2012082056 A8, vol.14, 2013.

N. Momeni, A novel blood-based biomarker for detection of autism spectrum disorders, Transl. Psychiatry, vol.2, issue.3, p.91, 2012.

R. Ballotti, C. Bertolotto, D. P. Bressac, L. M. De, and F. Lesueur, Mitf comme marqueur de predisposition a un cancer, WO2011083253 A1, vol.14, 2011.

C. Bertolotto, A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma, Nature, vol.480, issue.7375, pp.94-98, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01791271

A. Lepape, F. Venet, A. Villars, and G. Monneret, Procédé de détermination de la susceptibilité aux infections nosocomiales, 2013.

J. Demaret, Elevated plasmatic level of soluble IL-7 receptor is associated with increased mortality in septic shock patients, Intensive Care Med, vol.40, issue.8, pp.1089-1096, 2014.

J. B. Chimal, N. Sandoval, and B. Araceli, Méthode de diagnostic pour détecter une lésion rénale aiguë grâce à l'utilisation de la protéine de choc thermique de 72kda en tant que biomarqueur sensible, WO2011062469, vol.8, 2012.

J. Barrera-chimal, Hsp72 is an early and sensitive biomarker to detect acute kidney injury, EMBO Mol. Med, vol.3, issue.1, pp.5-20, 2011.

I. Cohen, M. Pevsner-foscher, D. Margel, J. Baniel, and O. Yossepowitch, Biomarqueurs urinaires pour diagnostic du cancer, WO2011016031 A3, vol.13, 2011.

D. Margel, M. Pevsner-fischer, M. Pesvner-fischer, J. Baniel, O. Yossepowitch et al., Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer, Eur. Urol, vol.59, issue.1, pp.113-119, 2011.

R. Shaw, T. Hong, and J. Smyth, Bin1 comme marqueur de pronostic dans une maladie cardiovasculaire, WO2010124240 A3, vol.31, 2011.

T. Hong, Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy, Heart Rhythm, vol.9, issue.6, pp.961-967, 2012.

F. Baehner, J. Baker, D. Cherbavaz, W. Cowens, M. Crager et al., Method for using gene expression to determine prognosis of prostate cancer, WO2012015765, vol.3, p.2012

B. Acres and B. Grellier, Biomarqueur pour la sélection de patients et procédés associés, WO2011003905 A1, vol.13, 2011.

Y. Chen, S. Hung, C. Shen, C. Chang, H. Lin et al., Allèles de hla associés à des réactions indésirables à un médicament et méthodes de détection afférentes, WO2007134235, vol.2, 2007.

W. Chung, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, vol.428, issue.6982, p.486, 2004.

S. Jalkanen, M. Salmi, and M. Jalkanen, A new biomarker for monitoring development of diseases and assessing the efficacy of therapies, WO2009053523, vol.1, p.2009

B. Ring, D. Seitz, and R. Beck, Tle3 comme marqueur de chimiothérapie, WO2009073478 A9, p.2009

S. A. Kulkarni, TLE3 as a candidate biomarker of response to taxane therapy, Breast Cancer Res. BCR, vol.11, issue.2, p.17, 2009.

D. Wong, F. Wei, and W. Liao, Method for exosomal biomarker detection by electric field-induced release and measurement, WO2012162563, vol.3, 2013.

F. Wei, J. Yang, and D. T. Wong, Detection of exosomal biomarker by electric field-induced release and measurement (EFIRM), Biosens. Bioelectron, vol.44, pp.115-121, 2013.

R. Rosell, J. Wei, and M. Taron, Circulating MicroRNA Signatures of TumorDerived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer, Clin. Lung Cancer, vol.10, issue.1, pp.8-9, 2009.